Clinical Trials Browser

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasms

Breast Neoplasms

Fludzoparib" and Anti-angiogenic

Breast Neoplasms

HER2-negative Metastatic Breast Cancer

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

HER2-negative Breast Cancer

Her2-negative Metastatic Breast Cancer

Breast Neoplasms, Patient Acceptance of Health Care

Breast Neoplasms

Breast Neoplasms

Brain Neoplasms, Breast Neoplasms, Meningeal Carcinomatosis

Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

Breast Neoplasms

Breast Neoplasms

Advanced Breast Cancer

Breast Neoplasms, Neoplasm Metastasis

HER2-positive Advanced Breast Cancer

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

HER2-negative Breast Cancer

Breast Diseases, Breast Neoplasms

Breast Neoplasms

Advanced Triple-Negative Breast Cancer

Triple Negative Breast Neoplasms

HER2-positive Advanced Breast Cancer

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Primary Breast Cancer

Clinical Trials

ORCHID

The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

AZALEA

Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer

TrasTUCAN

PRECIOUS

ATREZZO

ALPHABET

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

Adaptive Therapy for Post-Second-Line Advanced Breast Cancer

PemVin vs Vin in Previously Treated Metastatic Breast Cancer

Disitamab Vedotin in Combination with Metronomic Chemotherapy in Advanced HER2-expressing Breast Cancer.

SAFIR02_Breast

ORIENTA

EASOVCWDITHABC

PADMA

Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy

Detect V / CHEVENDO (Chemo vs. Endo)

Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis

Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer

Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer

SMMART Adaptive Clinical Treatment (ACT) Trial

Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer

CHEOPS

VEX

Vinorelbine Versus Gemcitabine Plus Vinorelbine in Metastatic Breast Cancer Patients

HER2-VIP

Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast Cancer

VinCaT

Oral Vinorelbine and Capecitabine in Advanced HER2-negative Breast Cancer

Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)

Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy

Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer

Platinum Rechallenge in Patients With Platinum-sensitive mTNBC

Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer

Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer

Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast Cancer

Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine

Cipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBC

Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients

Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer

Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer

Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D)

Trastuzumab & Pertuzumab Followed by T-DM1 in MBC

VICTORIANE

Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer

Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast Cancer

Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy